Life sciences and diagnostics company Danaher is moving focus on the growth opportunities for Life Sciences and Diagnostics segments. The company intends to float off its Environmental & Applied Solutions (EAS) segment into a separate publicly traded company. DHR would then be to further capitalize on the seen powerful growth in the other segments having been entrenched in the development of COVID-19 vaccines and therapeutics through its $21.4 bln acquisition of Cytiva in 2020. Cepheid also received Emergency Use Authorization … Continue reading “Danaher Floating off Environmental & Applied Solutions Segment Enhances Opportunity”